	US 12,286,619 B2
	Modulating lactogenic activity in mammalian cells
Shahram Misaghi, South San Francisco, CA (US); Masaru Ken Shiratori, South San Francisco, CA (US); Bradley Richard Snedecor, South San Francisco, CA (US); and Michael W. Laird, South San Francisco, CA (US)
Assigned to GENENTECH, INC., South San Francisco, CA (US)
Filed by GENENTECH, INC., South San Francisco, CA (US)
Filed on Sep. 29, 2020, as Appl. No. 17/036,075.
Application 17/036,075 is a continuation of application No. PCT/US2019/024774, filed on Mar. 29, 2019.
Claims priority of provisional application 62/649,963, filed on Mar. 29, 2018.
Prior Publication US 2021/0009988 A1, Jan. 14, 2021
Int. Cl. C12N 15/10 (2006.01); C12N 5/071 (2010.01); C12N 9/22 (2006.01); C12N 15/113 (2010.01)

CPC C12N 15/102 (2013.01) [C12N 5/0682 (2013.01); C12N 9/22 (2013.01); C12N 15/113 (2013.01); C12N 2310/20 (2017.05)]

19 Claims

1. A mammalian cell having reduced or eliminated lactogenic activity, wherein the cell comprises an exogenous nucleic acid sequence encoding a product of interest, wherein the expression of a pyruvate kinase muscle (PKM) polypeptide isoform in the cell is knocked down or knocked out, and wherein the PKM polypeptide isoform comprises a PKM-1 polypeptide isoform or a PKM-2 polypeptide isoform; wherein the cell is a CHO cell.